Skip to main content

Alcohol

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

AfaSci
AfaSciCA - Redwood City
1 program
1
AFA-281 is a small molecule, orally availablePhase 11 trial
Active Trials
NCT06719908Not Yet Recruiting20Est. Sep 2029
Vigonvita
VigonvitaChina - Suzhou
1 program
TPN171H tablet plus alcoholPHASE_11 trial
Active Trials
NCT05316428Completed19Est. Apr 2022

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
2028
2029
AfaSciAFA-281 is a small molecule, orally available
VigonvitaTPN171H tablet plus alcohol

Clinical Trials (2)

Total enrollment: 39 patients across 2 trials

NCT06719908AfaSciAFA-281 is a small molecule, orally available

A Phase I Study of the Interaction of Alcohol With Oral AFA-281 in Healthy Volunteers

Start: Jul 2025Est. completion: Sep 202920 patients
Phase 1Not Yet Recruiting
NCT05316428VigonvitaTPN171H tablet plus alcohol

A Study of the Hemodynamic Interactions of TPN171H Tablets & Alcohol in Healthy Male Subjects

Start: Feb 2022Est. completion: Apr 202219 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.